ReAlta Life Sciences

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Complement C1q / neutrophil effectors (myeloperoxidase, NETosis)Peptide
Chronic Obstructive Pulmonary Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
PegtarazimodPhase 2Steroid Refractory GVHD
Est. primary completion 2026-12 · NCT06343792 · CT.gov ↗
What to watch
PegtarazimodPhase 2/3Hypoxic-Ischemic Encephalopathy
Est. primary completion 2026-12 · NCT05778188 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 May 2026Topline resultRLS-0071 (pegtarazimod)Phase 2 AE-COPD proof-of-concept results presented at ATS 2026
ReAlta Life Sciences · Source ↗

Financial reports

No financial reports recorded.